Last updated on November 2017

A Phase 3, Multi-Center Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy f 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-1).


Brief description of study

A Phase 3, Multi-Center Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy f 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-1).

Detailed Study Description

The purpose of this study is to compare the safety and efficacy of RGN-259 to placebo for treatment of Neurotrophic Keratopathy (NK).

Clinical Study Identifier: TX14813

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Mandy Kessinger

The Eye Care Institute
Louisville, KY USA
  Connect »